Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
20. Dezember 2024 03:30 ET
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill,...
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia
18. Dezember 2024 21:35 ET
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd....
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
04. Dezember 2024 19:05 ET
|
Nxera Pharma
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ™ (daridorexant) 25 and 50 mg was recently approved and is expected...
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
12. November 2024 19:01 ET
|
Nxera Pharma
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd....
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
05. November 2024 02:00 ET
|
Nxera Pharma
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies...
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
01. November 2024 02:30 ET
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational...
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
23. Oktober 2024 03:00 ET
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won...
Nxera Pharma to Host R&D Day 2024
18. Oktober 2024 05:38 ET
|
Nxera Pharma
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date:...
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
01. Oktober 2024 02:04 ET
|
Nxera Pharma
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of...
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
01. Oktober 2024 02:02 ET
|
Nxera Pharma
QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024...